Alfonso Gonzalez Loeschen
Executive Vice President and Chief Executive Officer, NespressoNestlé
General ManagementView Profile →Chief Executive Officer, Roche Group · Roche Group
Thomas Schinecker leads Roche Group after a career spanning country management, sequencing, laboratory diagnostics and divisional leadership. His work has covered both the Diagnostics and Pharmaceuticals businesses, and he also serves as president of IFPMA.
Last reviewed: Nov 10, 2026
Chief Executive Officer, Roche Group
Roche Group
Last Reviewed: November 10, 2026
Thomas Schinecker leads Roche Group after a career spanning country management, sequencing, laboratory diagnostics and divisional leadership. His work has covered both the Diagnostics and Pharmaceuticals businesses, and he also serves as president of IFPMA.
Has led Roche Group since March 2023.
Previously served as chief executive of Roche Diagnostics and briefly as interim chief executive of Roche Pharmaceuticals.
Became president of the International Federation of Pharmaceutical Manufacturers and Associations in 2025.
Schinecker joined Roche in 2003 through its Perspectives management-development program. Over the following two years, his assignments took him to Singapore, Basel, Vienna and Mannheim. He subsequently became head of marketing and sales at Roche Diagnostics Austria in 2005, then moved to Stockholm as general manager of the Swedish diagnostics business in 2008.
In 2011, he transferred to the United States as lifecycle leader for Sequencing Solutions, working in Branford and Madison. He returned to Germany in 2013 to serve as general manager of Roche Diagnostics Germany and Roche Holding Germany, with responsibilities based in Mannheim and Grenzach.
His next appointment was in Rotkreuz, Switzerland, where he became global head of Centralized and Point of Care Solutions in 2018. In August 2019, Roche appointed him chief executive of its Diagnostics Division and a member of the Corporate Executive Committee.
During the subsequent leadership transition, he served as interim chief executive of Roche Pharmaceuticals in January and February 2023. He became chief executive of Roche Group in March 2023, succeeding Severin Schwan as Schwan moved to the group chairmanship.
His external work includes the innovation board of Labor Berlin, a Charité and Vivantes organization, from 2020, and the foundation boards of IMD and the Lucerne Festival from 2024. In 2025, he became IFPMA president and chair of the Biopharmaceutical CEOs Roundtable, and joined Chugai Pharmaceutical’s board.
Schinecker earned a BA in genetics at the University of Salzburg in 1997, an MS in molecular biology at New York University in 2000 and a PhD in molecular biology at NYU in 2003.